Jasper Therapeutics, Inc. (JSPR)
Oxford Ledge is still expanding full research coverage of JSPR. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
A clinical-stage biotech company developing briquilimab, a monoclonal antibody targeting mast cell survival signals for treating chronic urticarias and asthma.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- DEF 14A Proxy statement for shareholder vote 2026-06-15
- 8-K Delisting / transfer of listing 2026-06-09
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-06-01
- 8-K Departure/election of directors or officers; Financial statements and exhibits 2026-05-21
- 10-Q Quarterly financial report (unaudited) 2026-05-14
Source: SEC EDGAR.
Annual results
5 years of annual figures for JSPR, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | — | -$75.8M | -$3.95 |
| 2024 | — | -$71.3M | -$4.89 |
| 2023 | — | -$64.5M | -$6.18 |
| 2022 | — | -$37.7M | -$10.33 |
| 2021 | — | -$30.6M | -$2.69 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for JSPR. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open JSPR in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.